28394217|t|A Randomized, Head-to-Head Study of Virtual Reality Exposure Therapy for Posttraumatic Stress Disorder
28394217|a|Virtual reality exposure therapy (VRET) is one of the few interventions supported by randomized controlled trials for the treatment of combat-related posttraumatic stress disorder (PTSD) in active duty service members. A comparative effectiveness study was conducted to determine if virtual reality technology itself improved outcomes, or if similar results could be achieved with a control exposure therapy (CET) condition. Service members with combat-related PTSD were randomly selected to receive nine weeks of VRET or CET. Assessors, but not therapists, were blinded. PTSD symptom improvement was assessed one week and 3 months after the conclusion of treatment using the clinician-administered PTSD scale (CAPS). A small crossover component was included. Results demonstrated that PTSD symptoms improved with both treatments, but there were no statistically significant differences between groups. Dropout rates were higher in VRET. Of those who received VRET, 13/42 (31%) showed >30% improvement on the CAPS, versus 16/43 (37%) who received CET. Three months after treatment, >30% improvement was seen in 10/33 (30%) of VRET participants and 12/33 (36%) in CET. Participants who crossed over (n = 11) showed no statistically significant improvements in a second round of treatment, regardless of condition. This study supported the utility of exposure therapy for PTSD, but did not support additional benefit by the inclusion of virtual reality.
28394217	2	12	Randomized	T062	C0034656
28394217	14	26	Head-to-Head	T080	C0205556
28394217	27	32	Study	T062	C2603343
28394217	36	68	Virtual Reality Exposure Therapy	T061	C3494470
28394217	73	102	Posttraumatic Stress Disorder	T048	C0038436
28394217	103	135	Virtual reality exposure therapy	T061	C3494470
28394217	137	141	VRET	T061	C3494470
28394217	161	174	interventions	T058	C1273869
28394217	175	184	supported	T077	C1521721
28394217	188	216	randomized controlled trials	T062,T170	C0282440
28394217	225	234	treatment	T061	C0087111
28394217	238	282	combat-related posttraumatic stress disorder	T048	C0038436
28394217	284	288	PTSD	T048	C0038436
28394217	293	312	active duty service	T033	C2135638
28394217	313	320	members	T098	C0680022
28394217	324	355	comparative effectiveness study	T062	C1579762
28394217	386	401	virtual reality	T066	C0871582
28394217	402	412	technology	T090	C0039421
28394217	420	428	improved	T033	C0184511
28394217	429	437	outcomes	T080	C0085415
28394217	445	452	similar	T080	C2348205
28394217	453	460	results	T169	C1274040
28394217	470	478	achieved	T053	C0001072
28394217	486	510	control exposure therapy	T061	C0870527
28394217	512	515	CET	T061	C0870527
28394217	517	526	condition	T080	C0348080
28394217	528	535	Service	T057	C0557854
28394217	536	543	members	T098	C0680022
28394217	549	568	combat-related PTSD	T048	C0038436
28394217	574	582	randomly	T080	C0439605
28394217	583	591	selected	T052	C1707391
28394217	595	602	receive	T080	C1514756
28394217	608	613	weeks	T079	C0439230
28394217	617	621	VRET	T061	C3494470
28394217	625	628	CET	T061	C0870527
28394217	630	639	Assessors	T097	C0401803
28394217	649	659	therapists	T097	C0871525
28394217	666	673	blinded	T062	C0150108
28394217	675	679	PTSD	T048	C0038436
28394217	680	687	symptom	T184	C1457887
28394217	688	699	improvement	T077	C2986411
28394217	704	712	assessed	T052	C1516048
28394217	717	721	week	T079	C0439230
28394217	728	734	months	T079	C0439231
28394217	745	755	conclusion	T078	C1707478
28394217	759	768	treatment	T061	C0087111
28394217	779	812	clinician-administered PTSD scale	T170	C0349674
28394217	814	818	CAPS	T170	C0349674
28394217	823	828	small	T081	C0700321
28394217	853	861	included	T169	C0332257
28394217	863	870	Results	T169	C1274040
28394217	889	893	PTSD	T048	C0038436
28394217	894	902	symptoms	T184	C1457887
28394217	903	911	improved	T033	C0184511
28394217	922	932	treatments	T061	C0087111
28394217	952	977	statistically significant	T081	C0237881
28394217	978	989	differences	T033	C3842396
28394217	998	1004	groups	T078	C0441833
28394217	1006	1013	Dropout	T098	C0030686
28394217	1014	1019	rates	T081	C1521828
28394217	1025	1031	higher	T080	C0205250
28394217	1035	1039	VRET	T061	C3494470
28394217	1054	1062	received	T080	C1514756
28394217	1063	1067	VRET	T061	C3494470
28394217	1093	1104	improvement	T077	C2986411
28394217	1112	1116	CAPS	T170	C0349674
28394217	1141	1149	received	T080	C1514756
28394217	1150	1153	CET	T061	C0870527
28394217	1161	1167	months	T079	C0439231
28394217	1174	1183	treatment	T061	C0087111
28394217	1190	1201	improvement	T077	C2986411
28394217	1229	1233	VRET	T061	C3494470
28394217	1234	1246	participants	T098	C0679646
28394217	1266	1269	CET	T061	C0870527
28394217	1271	1283	Participants	T098	C0679646
28394217	1288	1300	crossed over	T033	C0243095
28394217	1320	1345	statistically significant	T081	C0237881
28394217	1346	1358	improvements	T077	C2986411
28394217	1364	1370	second	T081	C0205436
28394217	1380	1389	treatment	T061	C0087111
28394217	1391	1401	regardless	T080	C3641650
28394217	1405	1414	condition	T080	C0348080
28394217	1421	1426	study	T062	C2603343
28394217	1427	1436	supported	T077	C1521721
28394217	1441	1448	utility	T169	C3669222
28394217	1452	1468	exposure therapy	T061	C0870527
28394217	1473	1477	PTSD	T048	C0038436
28394217	1491	1498	support	T077	C1521721
28394217	1499	1509	additional	T169	C1524062
28394217	1510	1517	benefit	T081	C0814225
28394217	1525	1534	inclusion	T080	C1512693
28394217	1538	1553	virtual reality	T066	C0871582